^
    Back
    Association details:
    Biomarker:DDR
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    1640 - Correlations of DNA damage response gene alterations with response to immune checkpoint inhibitors are different in solid tumors

    Published date:
    03/10/2021
    Excerpt:
    DDR alterations are associated with ICIs efficacy in melanoma (P = 0.0007), colorectal cancer (P = 0.0012), NSCLC (P = 0.0224), bladder cancer (P = 0.0439), and breast cancer (P = 0.0451).